Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial
帕博利珠单抗和奥拉帕尼(POLAR)维持治疗转移性胰腺癌(伴或不伴同源修复缺陷):一项基于生物标志物的II期临床试验
期刊:
影响因子:
doi:10.21203/rs.3.rs-7334701/v1
Park, Wungki; O'Connor, Catherine; Chou, Joanne; Hilmi, Marc; Tarcan, Zeynep; Schwartz, Carly; Larsen, Mary; Chatila, Walid; Sivaprakasam, Karthigayini; Umeda, Shigeaki; Perry, Maria; Varghese, Anna; Yu, Kenneth; Balogun, Fiyinfolu; Zervoudakis, Alice; Katz, Seth; Kim, Tae-Hyung; Zhao, Ken; Richards, Allison; Lecomte, Nicolas; Muldoon, Daniel; Karnoub, Elias; Yang, Jessica; El-Dika, Imane; Rao, Devika; Smita, Joshi; Foote, Michael; Sugarman, Ryan; Harding, James; Epstein, Andrew; Kelsen, David; Chalasani, Sree; Keane, Fergus; Schoenfeld, Joshua; Singhal, Anupriya; Diguglielmo, Erin; Bandlamudi, Chaitanya; Song, Junmin; Ozkan, Hulya Sahin; Hong, Jungeui; Zhang, Haochen; Cardenas, Agustin; Lao, Maria; Melchor, Jerry; Shah, Ronak; Kang, Wenfei; Mazzoni, Francesca; Soares, Kevin; Donoghue, Mark; Balachandran, Vinod; Schattner, Mark; Santos, Ernesto; Rolston, Vineet; Reyngold, Marsha; Wei, Alice; Homsi, Ramzi; Tipping, Murray; Basturk, Olca; Berger, Michael; Do, Richard; Jarnagin, William; Riaz, Nadeem; Pe'er, Dana; Capanu, Marinela; Iacobuzio-Donahue, Christine; O'Reilly, Eileen